|
1
|
Hashimoto Y, Shiina M, Kato T, Yamamura S,
Tanaka Y, Majid S, Saini S, Shahryari V, Kulkarni P, Desgupta P, et
al: The role of miR-24 as a race related genetic factor in prostate
cancer. Oncotarget. 8:16581–16593. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu J, He J, Kuang Y, Wang Z, Sun Z, Zhu H
and Liu X: Expression and significance of 90K/Mac-2BP in prostate
cancer. Exp Ther Med. 5:181–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade P, Zhang S, Zeng H,
Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015.
CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Etzioni R, Urban N, Ramsey S, McIntosh M,
Schwartz S, Reid B, Radich J, Anderson G and Hartwell L: The case
for early detection. Nat Rev Cancer. 3:243–252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee RC, Feinbaum RL and Ambros V: The C.
Elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen JF, Mandel EM, Thomson JM, Wu Q,
Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of
microRNA-1 and microRNA-133 in skeletal muscle proliferation and
differentiation. Nat Genet. 38:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS,
Chen JS and Cheng AJ: miR-196, an emerging cancer biomarker for
digestive tract cancers. J Cancer. 7:650–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee H, Lee S, Bae H, Kang HS and Kim SJ:
Genome-wide identification of target genes for miR-204 and miR-211
identifies their proliferation stimulatory role in breast cancer
cells. Sci Rep. 6:252872016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang CY, Hua L, Sun J, Yao KH, Chen JT,
Zhang JJ and Hu JH: MiR-211 inhibits cell proliferation and
invasion of gastric cancer by down-regulating SOX4. Int J Clin Exp
Pathol. 8:14013–14020. 2015.PubMed/NCBI
|
|
15
|
Jiang G, Cui Y, Yu X, Wu Z, Ding G and Cao
L: miR-211 suppresses hepatocellular carcinoma by downregulating
SATB2. Oncotarget. 6:9457–9466. 2015.PubMed/NCBI
|
|
16
|
Deng B, Qu L, Li J, Fang J, Yang S, Cao Z,
Mei Z and Sun X: MiRNA-211 suppresses cell proliferation, migration
and invasion by targeting SPARC in human hepatocellular carcinoma.
Sci Rep. 6:266792016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia B, Yang S, Liu T and Lou G: miR-211
suppresses epithelial ovarian cancer proliferation and cell-cycle
progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye L, Wang H and Liu B: miR-211 promotes
non-small cell lung cancer proliferation by targeting SRCIN1. Tumor
Biol. 37:1151–1157. 2016. View Article : Google Scholar
|
|
19
|
Motamed K: SPARC (osteonectin/BM-40). Int
J Biochem Cell Biol. 31:1363–1366. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shin M, Mizokami A, Kim J, Ofude M, Konaka
H, Kadono Y, Kitagawa Y, Miwa S, Kumaki M, Keller ET and Namiki M:
Exogenous SPARC suppresses proliferation and migration of prostate
cancer by interacting with integrin β1. Prostate. 73:1159–1170.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi Q, Bao S, Maxwell JA, Reese ED,
Friedman HS, Bigner DD, Wang XF and Rich JN: Secreted protein
acidic, rich in cysteine (SPARC), mediates cellular survival of
gliomas through AKT activation. J Biol Chem. 279:52200–52209. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thomas R, True LD, Bassuk JA, Lange PH and
Vessella RL: Differential expression of osteonectin/SPARC during
human prostate cancer progression. Clin Cancer Res. 6:1140–1149.
2000.PubMed/NCBI
|
|
23
|
Zhao ZS, Wang YY, Chu YQ, Ye ZY and Tao
HQ: SPARC is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 16:260–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Massi D, Franchi A, Borgognoni L, Reali UM
and Santucci M: Osteonectin expression correlates with clinical
outcome in thin cutaneous malignant melanomas. Hum Pathol.
30:339–344. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sharma S, Xing F, Liu Y, Wu K, Said N,
Pochampally R, Shizawa Y, Lin HK, Balaji KC and Watabe K: Secreted
Protein Acidic and Rich in Cysteine (SPARC) mediates metastatic
dormancy of prostate cancer in bone. J Biol Chem. 291:19351–19363.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adensines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rusthoven CG, Carlson JA, Waxweiler TV,
Yeh N, Raben D, Flaig TW and Kavanagh BD: The prognostic
significance of Gleason scores in metastatic prostate cancer. Urol
Oncol. 32:707–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cuzick J, Yang ZH, Fisher G, Tikishvili E,
Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, et
al: Prognostic value of PTEN loss in men with conservatively
managed localized prostate cancer. Br J Cancer. 108:2582–2589.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Noh BJ, Sung JY, Kim YW, Chang SG and Park
YK: Prognostic value of ERG, PTEN, CRISPR3 and SPINK1 in predicting
biochemical recurrence in prostate cancer. Oncol Lett.
11:3621–3630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duan K, Ge YC, Zhang XP, Wu SY, Feng JS,
Chen SL, Zhang LI, Yuan ZH and Fu CH: miR-34a inhibits cell
proliferation in prostate cancer by downregulating of SIRT1
expression. Oncol Lett. 10:3223–3227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bier A, Giladi N, Kronfeld N, Lee HK,
Cazacu S, Finniss S, Xiang C, Poisson L, deCarvalho AC, Slavin S,
et al: MicroRNA-137 is downregulated in glioblastoma and inhibits
the stemness of glioma stem cells by targeting RTVP-1. Oncotarget.
4:665–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu C, Liao Z, Cai M and Zhang G:
MicroRNA-320a downregulation mediates human liver cancer cell
proliferation through the Wnt/β-catenin signaling pathway. Oncol
Lett. 13:573–578. 2017. View Article : Google Scholar : PubMed/NCBI
|
